1-3 of 3
Rolf Stahel
Close
Sort by
Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Michael Pfreundschuh, MD, Evelyn Kuhnt, Lorenz Trümper, MD, Anders Osterborg, MD, PhD, Marek Trneny, MD, Lois Shepherd, MD, Devinder S Gill, MD, Jan Walewski, MD, Ruth Pettengell, FRACP, PhD, Ulrich Jäger, MD, Pier Luigi Zinzani, MD, PhD, Ofer Shpilberg, MD, MPH, Stein Kvaloy, MD, Mads Hansen, MD, Rolf Stahel, MD, Noel Milpied, MD, Armando Lopez-Guillermo, MD, Sandra Grass, MD, Niels Murawski, MD, Viola Pöschel, Markus Löffler
Journal: Blood
Blood (2010) 116 (21): 111.
https://doi.org/10.1182/blood.V116.21.111.111
Published: 2010
Journal Articles

Factors Prognostic for Response and Event Free Survival and Treatment Related Toxicity in 306 Patients with Follicular or Mantle Cell Lymphoma Randomized to Single Agent Rituximab Given at the Standard or at a Prolonged Schedule.

Michele Ghielmini, Kaspar Rufibach, Gilles Salles, Sergio Cogliatti, Leda Leoncini-Franscini, Claire Leger-Falandry, Martin Fey, Thomas Cerny, Giovanni Martinelli, Rolf Stahel, Andreas Lohri, Nicolas Ketterer, Martin Wernli
Journal: Blood
Blood (2004) 104 (11): 588.
https://doi.org/10.1182/blood.V104.11.588.588
Published: 2004
Journal Articles

CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells

Silke Aigner, Zev M. Sthoeger, Mina Fogel, Erich Weber, Jürg Zarn, Michael Ruppert, Yvonka Zeller, Dietmar Vestweber, Rolf Stahel, Marei Sammar, Peter Altevogt
Journal: Blood
Blood (1997) 89 (9): 3385–3395.
https://doi.org/10.1182/blood.V89.9.3385
Published: 1997